X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
0
Europe
Canada
0
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-january-10-2024-93939.pdf
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-june-7-2023-80553.pdf
https://health.economictimes.indiatimes.com/news/pharma/nagpur-paediatricians-warn-against-rampant-use-of-cough-syrups/94758394
https://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-initiates-advance-2-phase-3-trial-axs-05
https://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-announces-publication-pivotal-ascend-phase-2
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-may-4-2022-1651646484.pdf
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-february-9-2022-1644385243.pdf
https://www.pharmacompass.com/pdf/news/gsk-consumer-healthcare-issues-voluntary-nationwide-recall-of-childrens-robitussin-1592884945.pdf
https://www.federalregister.gov/documents/2019/12/02/2019-25946/morton-grove-pharmaceuticals-inc-et-al-withdrawal-of-approval-of-21-abbreviated-new-drug
https://www.prnewswire.com/news-releases/avanir-pharmaceuticals-inc-to-continue-clinical-development-of-investigational-avp-786-for-the-treatment-of-agitation-in-patients-with-alzheimers-dementia-300956033.html
https://endpts.com/reeling-from-a-hefty-civil-and-criminal-settlement-avanir-stumbles-into-phiii-alzheimers-failure/
https://www.fiercepharma.com/pharma/otsuka-s-avanir-agrees-to-pay-108m-over-neudexta-kickbacks-probe
http://www.pmlive.com/pharma_news/otsukas_alzheimers_agitation_drug_hits_the_mark_1282509
https://www.fiercepharma.com/pharma/avanir-nearing-doj-settlement-neudexta-marketing-otsuka-estimates-120m
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-june-20-2018-1529474392.pdf
https://www.fiercepharma.com/pharma/medicare-wants-insurers-to-monitor-suspicious-prescribing-laughing-drug-nuedexta
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203133
https://www.drugtargetreview.com/article/21644/ketamine-depression/
http://www.prnewswire.com/news-releases/eisai-acquires-all-global-development-and-marketing-rights-for-chronic-weight-management-treatment-lorcaserin-hci-300385785.html
http://www.business-standard.com/article/companies/200-out-of-500-combinations-examined-have-been-found-irrational-govt-sources-116111601364_1.html
http://www.prnewswire.com/news-releases/allergan-and-perrigo-receive-fda-approval-of-three-extended-release-products-equivalent-to-mucinex-and-mucinex-dm-300141198.html
http://www.fiercepharmamanufacturing.com/story/labeling-foul-involving-acetaminophen-leads-rb-recall-135-lots-mucinex/2015-04-22
http://www.biospace.com/News/cough-medicine-ingredient-may-aid-type-2-diabetes/369183/source=Featured
http://www.actavis.com/news/news/thomson-reuters/actavis-will-appeal-injunction-requiring-continued
Market Place
Share 
